Questions about Atrial Fibrillation? Get answers from our expert.

Propafenone Hydrochloride

Pronunciation

Class: Class Ic Antiarrhythmics
VA Class: CV300
Chemical Name: 1-Propanone,1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3- phenylpropan-1-one hydrochloride
Molecular Formula: C21H27NO3
CAS Number: 34183-22-7
Brands: Rythmol

Introduction

Local anesthetic-type class IC antiarrhythmic agent.3 10 38 134 289 310

Uses for Propafenone Hydrochloride

Paroxysmal Atrial Fibrillation/Flutter and Paroxysmal Supraventricular Tachyarrhythmias

Used (as conventional [immediate-release] tablets) to prolong the time to recurrence of symptomatic, disabling paroxysmal supraventricular tachycardia (PSVT) (e.g., AV nodal reentrant tachycardia or AV reentrant tachycardia [Wolff-Parkinson-White syndrome, WPW syndrome]) and symptomatic, disabling paroxysmal atrial fibrillation/flutter (PAF) in patients without structural heart disease.1 3 67 68 90 91 92 93 94 99 101 102 105 107 108 109 110 132 133 173 187 206 211

Comparably effective to quinidine, disopyramide, flecainide, procainamide, sotalol in preventing recurrences of PAF and maintaining sinus rhythm following successful cardioversion of atrial fibrillation.3 68 89 129 133 183 200 201 202 204 205

Slideshow: Atrial Fibrillation - Stroke Prevention Guidelines & Treatment Options

Used (as extended-release capsules) to prolong the time to recurrence of symptomatic PAF in patients without structural heart disease.289

Safety and efficacy of extended-release capsules not established in patients with exclusively PSVT or atrial flutter.289

Safety and efficacy not established in patients with chronic atrial fibrillation.1 289 Generally, do not use to control ventricular rate in patients with atrial fibrillation, but conventional (immediate-release) tablets may be useful in controlling ventricular response rate in patients with stable but rapid atrial fibrillation/flutter and ventricular preexcitation via an accessory pathway (e.g., WPW syndrome).269 272 288

Treatment of PSVT (using IV propafenone [IV dosage form not commercially available in the US]) in patients with preserved ventricular function refractory to vagal maneuvers, IV adenosine (the drug of choice), AV nodal blocking agents (e.g., calcium-channel blocking agents), and electrical cardioversion therapy or in whom such therapy is not feasible or desirable.288

Conversion of Atrial Fibrillation to Normal Sinus Rhythm

Used (as conventional [immediate-release] tablets and IV) in the conversion of recent-onset (≤48 hours duration)310 atrial fibrillation (e.g., after open-heart surgery) to normal sinus rhythm; some consider propafenone first-line therapy.15 68 88 89 90 101 103 104 109 110 111 195 196 197 198 199 207 208 211 272

Self-administration for Conversion of PAF

Used for out-of-hospital self-administration (“pill-in-the-pocket” approach) as a single oral loading dose (conventional (immediate-release) tablets) to terminate recent-onset PAF; may result in reduced hospitalizations and emergency room visits of patients with mild or no heart disease.158 160 211 272 290 294 309

Ventricular Arrhythmias

As conventional (immediate-release) tablets, suppresses and prevents recurrence of documented life-threatening ventricular arrhythmias (e.g., sustained VT, VF).1 3 (See Mortality under Cautions.)

Propafenone Hydrochloride Dosage and Administration

General

  • Individualize dosage according to individual requirements, response, tolerance, general condition, and cardiovascular status.1 2 3 9 15 28 47 68

  • Initiate therapy (conventional [immediate-release] tablets) for life-threatening ventricular arrhythmias in a hospital.1 273

  • Clinical and ECG evaluation (e.g., Holter monitoring) is recommended during propafenone therapy.1 3 289

Administration

Administer orally.

Has been administered IV.3 17 31 76 88 89 90 95 96 97 98 100 102 104 106 110 119 122 133 183

Oral Administration

Administer conventional (immediate-release) tablets in a consistent manner relative to food intake.6 9 128 256 272 273

Administer conventional (immediate-release) tablets in 3 equally divided doses daily at 8-hour intervals.1

Administer extended-release capsules in equally divided doses every 12 hours without regard to meals.289

Swallow extended-release capsules whole; do not crush.289

Avoid grapefruit juice.272 273 (See Drugs, Foods, and Herbal Supplements under Interactions.)

Dosage

Adjust dosage carefully according to individual requirements and response, patient tolerance, and the general condition and cardiovascular status of the patient.1 2 3 9 15 28 47 68 289

Consider dosage reduction in patients who develop excessive prolongation of the PR interval, excessive QRS widening, or second- or third-degree AV block.1 2 3 15 90

Usually do not use oral loading doses (conventional [immediate-release] tablets) since acute toxicity may occur.3 6 272 273 However, oral loading doses (e.g., 450–750 mg as conventional [immediate-release] tablets) have been used with apparent safety for conversion of recent-onset atrial fibrillation to normal sinus rhythm in individuals without heart failure.68 89 90 101 109 160 195 196 208 272

Pediatric Patients

Supraventricular Arrhythmias
Oral (conventional [immediate-release] tablets)

Maximum daily dosage 600 mg/m2.272

Adults

Paroxysmal Atrial Fibrillation/Flutter and Paroxysmal Supraventricular Tachyarrhythmias
Oral (conventional [immediate-release] tablets)

Initially, 150 mg every 8 hours.1 2 68

Increase dosage after 3–4 days to 225 mg 3 times daily (every 8 hours) if necessary.1 68 90

If desired therapeutic response is not attained after an additional 3–4 days, increase dosage to 300 mg 3 times daily (every 8 hours).1 68 90

Oral (extended-release capsules)

Initially, 225 mg every 12 hours.289

Increase dosage after ≥5 days to 325 mg every 12 hours if necessary.289

If desired therapeutic response is not attained after an additional 5 days, increase dosage to 425 mg every 12 hours.289

If a dose is missed, only administer the next scheduled dose; do not double next dose.289

When switching from conventional (immediate-release) tablets to extended-release capsules, the dosage conversion ratio is not a 1:1 substitution (e.g., a patient who currently is receiving 150 mg every 8 hours of conventional (immediate-release) tablets may be switched to 325 mg of extended-release capsules every 12 hours).289 308

Conversion of Atrial Fibrillation to Normal Sinus Rhythm
Oral (conventional [immediate-release] tablets)

150–600 mg, as a single dose.158 211

IV

2 mg/kg (over 10 minutes) as a single dose.158 211

Self-administration for Conversion of PAF
Oral (conventional [immediate-release] tablets)

Adults weighing 70 kg or more: May use a single oral loading dose of 600 mg 5 minutes after noting the onset of palpitations.290 309

Adults weighing < 70 kg: May use a single oral loading dose of 450 mg 5 minutes after noting the onset of palpitations.290 309

Do not take more than a single oral dose during a 24-hour period.290

Ventricular Arrhythmias
Oral (conventional [immediate-release] tablets)

Initially, 150 mg every 8 hours.1 2 68

Increase dosage after 3–4 days to 225 mg 3 times daily if necessary.1 68 90

If desired therapeutic response is not attained after an additional 3–4 days, increase dosage to 300 mg 3 times daily.1 68 90

Prescribing Limits

Pediatric Patients

Supraventricular Arrhythmias
Oral (conventional [immediate-release] tablets)

Maximum daily dosage is 600 mg/m2.272

Adults

Supraventricular Arrhythmias
Oral (conventional [immediate-release] tablets)

Maximum daily dosage is 900 mg.1 9 90 272 273

Life-threatening Ventricular Arrhythmias
Oral (conventional [immediate-release] tablets)

Maximum daily dosage is 900 mg.1 9 90 272 273

Special Populations

Hepatic Impairment

When conventional (immediate-release) tablets are used, reduce dosage by approximately 70–80%; monitor patients for signs of toxicity, including hypotension, somnolence, bradycardia, conduction disturbances, seizures, and/or ventricular arrhythmias.1 115 193

Geriatric Patients and Those with Myocardial Damage

During initiation of therapy (conventional [immediate-release] tablets), gradual dosage escalation should be performed in geriatric patients and those with marked previous myocardial ischemia.1 3

Cautions for Propafenone Hydrochloride

Contraindications

  • Patients with uncontrolled CHF (conventional [immediate-release] tablets),1 CHF (extended-release capsules).289

  • Cardiogenic shock.1 3 289

  • Sinoatrial, AV, or intraventricular disorders of impulse generation and/or conduction (e.g., sick sinus node syndrome, AV block) unless an artificial pacemaker is present.1 3 6 234 289

  • Bradycardia.1 3 289

  • Severe hypotension.1 3 289

  • Bronchospastic disorders.1 289

  • Marked electrolyte imbalance.1 3 289

  • Known hypersensitivity to propafenone.1 289

Warnings/Precautions

Warnings

Mortality

In CAST study, excessive rate of mortality and nonfatal cardiac arrest reported in patients with asymptomatic or mildly symptomatic non-life-threatening ventricular arrhythmias and recent MI (>6 days but <2 years previously) who were receiving encainide or flecainide compared with placebo.1 116 117 149 155 234 235 289 The applicability of these results to other populations (e.g., those without recent MI) or to other antiarrhythmic drugs is uncertain.1 6 48 62 118 168 234 235

Limit use of propafenone or other class I agents in patients with ventricular arrhythmias to those with life-threatening arrhythmias;1 116 117 use in patients with less severe ventricular arrhythmias, even when symptomatic, is not recommended.1

Arrhythmogenic and Cardiac Conduction Effects

Potential for new and/or more severe arrhythmias,1 2 3 4 6 9 15 16 17 18 47 58 67 68 75 113 116 168 230 232 233 234 235 especially in those with CHF (NYHA class III or IV]) or myocardial ischemia.289

Risk of clinically important conduction disturbances;1 6 75 136 151 310 degree of lengthening of PR and QRS intervals may increase progressively with increasing dosage and plasma propafenone concentrations.1 2 47 233 289 1 2 6 9 47 68 168 233 289

Reduce dosage or discontinue the drug if 2nd- or 3rd-degree AV block occurs.1 (See Contraindications under Cautions.)

Evaluate clinical status and ECG prior to and during propafenone therapy to monitor for appearance of arrhythmias and to determine the need for continued therapy.1 2 168

Monitor patients with permanent artificial pacemakers and, if necessary, reprogram pacemakers.1 2 3 225 229 289

Cardiovascular Effects

Potential for new or worsened CHF, particularly in patients with preexisting heart failure or ejection fraction <30%.1 2 3 4 9 13 17 47 68 75 117 289

Use with caution (conventional [immediate-release] tablets) in patients with a history of CHF or myocardial dysfunction.1 117 168 235 236

Discontinue therapy if CHF worsens (unless caused by the cardiac arrhythmia); fully compensate CHF before therapy is reinitiated.1

Hematologic Effects

Possible reversible granulocytopenia3 47 and agranulocytosis.1 47

Carefully evaluate patients in whom unexplained fever and/or decreased WBC counts occur (especially during the initial 3 months of therapy).1 289 WBC counts generally return to normal within 2 weeks following discontinuance.1 289

Bronchospastic Disease

Possible inhibition of bronchodilation produced by endogenous catecholamines; use generally not recommended in patients with asthma/bronchospastic disease or nonallergic bronchospastic disease (e.g., chronic bronchitis, emphysema).1 3 15 40 67 68 173 215 289 (See Contraindications under Cautions.)

General Precautions

Hepatic Impairment

Extensively metabolized in liver; use with caution in those with hepatic impairment.1 3 8 11 15 33 68 178 289

Renal Impairment

Several metabolites excreted by kidneys; use with caution in those with renal impairment.1 13 289

Antinuclear Antibodies.

Possible positive antinuclear antibody (ANA) titers.1 289

Monitor carefully patients who develop an abnormal ANA test following initiation of therapy; consider discontinuation of therapy if titers remain elevated or increase further.1 289

Impaired Spermatogenesis

Transient, reversible decreases (within normal range) in sperm count may occur.1 289

Myasthenia Gravis

Possible exacerbation of myasthenia gravis.1 52 289 Avoid use in patients with this condition.3

Specific Populations

Pregnancy

Category C.1 289

Lactation

Distributed into milk.3 289 Caution if used in nursing women.289

Pediatric Use

Safety and efficacy not established in children <18 years of age.1 273 289

Has been used successfully and without unusual adverse effects in a limited number of infants and children for the management of various refractory supraventricular (e.g., PSVT, junctional ectopic tachycardia, atrial fibrillation or flutter) and ventricular (e.g., VPCs, VT) arrhythmias.3 68 146 212 213 214 216 217 218 220 272 However, adenosine is the drug of choice for treatment of supraventricular tachycardia in children.288 310

Geriatric Use

Conventional (immediate-release) tablets: Insufficient experience to determine whether geriatric patients ≥65 years of age respond differently than younger adults.1 Select dosage with caution; start at the lower end of dosing range due to greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy.1

Extended-release capsules: No substantial differences in safety and efficacy relative to younger adults, but increased sensitivity cannot be ruled out.289

Hepatic Impairment

Extensively metabolized in liver; use with caution.1 3 8 11 15 33 68 178 289 Careful monitoring for excessive pharmacological effects recommended.1 Reduce dosage.1 3 8 11 15 33 68 178 289 (See Special Populations under Dosage and Administration.)

Renal Impairment

Use with caution.1 Careful monitoring for excessive pharmacological effects recommended.1

Common Adverse Effects

Conventional (immediate-release) tablets: Unusual taste, nausea and/or vomiting, dizziness, constipation, headache, fatigue, blurred vision, and weakness.1 First-degree AV block and intraventricular conduction delay in patients with ventricular arrhythmia.1

Extended-release capsules: Constipation, diarrhea, dry mouth, nausea, vomiting, unusual taste, fatigue, weakness, dizziness, headache, somnolence, anxiety, dyspnea, ecchymosis, upper respiratory infection, abnormalities in liver function tests (e.g., increased serum concentrations of alkaline phosphatase), hematuria.289

Interactions for Propafenone Hydrochloride

Metabolized by CYP2D6 and to a lesser extent by CYP1A2, CYP3A4.1 131 190 285 286 289

Inhibits CYP2D6.1 289

Drugs and Foods Affecting Hepatic Microsomal Enzymes

Pharmacokinetic interactions likely with drugs that are inhibitors, inducers, or substrates of CYP2D6, CYP1A2, or CYP3A4 with possible alteration in metabolism of propafenone and/or other drugs.1 131 190 285 286 289 Monitor patients.1

Drugs Metabolized by p-Glycoprotein Transporter

Effect of propafenone on the p-glycoprotein transport system not evaluated.1 289

Drugs Affecting QT Interval

Do not use with drugs that prolong the QT interval.289

Antiarrhythmic Agents

Use extreme caution when propafenone is administered with 1 or more antiarrhythmic agents.3 68 288

Reserve concomitant use for management of life-threatening arrhythmias unresponsive to monotherapy with propafenone (immediate-release tablets) or another antiarrhythmic agent.3 68 288

Do not use propafenone (extended-release capsules) with class Ia or III antiarrhythmic agents.289

Specific Drugs and Foods

Drug or Food

Interaction

Comments

Amiodarone

Possible increased incidence of cardiovascular effects1 13 287 288 289

Increased propafenone concentrations1 289

Concomitant use not recommended 1 289

β-adrenergic blocking agents (e.g., metoprolol, propranolol)

Increased β-adrenergic blocking agent concentrations and terminal elimination half-life1 246 247 289

Use concomitantly with caution; consider β-adrenergic blocking agent dosage reduction1 6 9 13 247 289

Calcium channel-blocking agents

No evidence of clinically important adverse interactions1 289

Cimetidine

Increased propafenone steady-state plasma concentrations1 289

Cyclosporine

Increased cyclosporine concentrations1 250 289

Desipramine

Increased propafenone concentrations1 289

Increased desipramine serum concentrations1

Use concomitantly with caution; reduce propafenone hydrochloride dosage1 131 190 285 286 289

Consider desipramine dosage reduction1

Digoxin

Increased serum or plasma digoxin concentrations1 3 9 85 124 125 245 279 280 281 282 283 289

Carefully monitor serum digoxin concentrations and adjust digoxin dosage 1 3 9 85 124 125 245 283 289

Diuretics

No evidence of clinically important adverse interactions1 289

Erythromycin

Increased propafenone concentrations1 289 1 131 190 285 286 289

Use concomitantly with caution; reduce propafenone hydrochloride dosage1 131 190 285 286 289

Fluoxetine

In extensive-metabolizer phenotypes, increased peak plasma concentrations and AUC of propafenone1 289

Grapefruit juice

Possible increased plasma concentrations of unchanged propafenone and potential adverse effects1 257 258 259 260 261 262 289

Avoid concomitant use272 273

Haloperidol

Increased haloperidol concentrations1 289

Use concomitantly with caution; consider haloperidol dosage reduction1 289

Imipramine

Increased imipramine concentrations1 289

Use concomitantly with caution; consider imipramine dosage reduction1 289

Ketoconazole

Increased propafenone concentrations1 131 190 285 286 289

Use concomitantly with caution; reduce propafenone hydrochloride dosage1 131 190 285 286 289

Lidocaine

Possible pharmacologic interaction (additive or antagonistic cardiac effects and additive toxicity) 1 2 9 13 122 289

Orlistat

Possible limited absorption of propafenone1 289

Possibility of severe adverse effects with abrupt discontinuance of orlistat1 289

Paroxetine

Increased propafenone concentrations1 131 190 285 286 289

Use concomitantly with caution; reduce propafenone hydrochloride dosage1 131 190 285 286 289

Phenobarbital

Decreased plasma propafenone concentrations3

Quinidine

Increased plasma propafenone concentrations1 3 123 289

Possible increased incidence of cardiovascular effects288

Concomitant use not recommended 1 289

Rifampin

Increased metabolism of propafenone resulting in decreased plasma propafenone concentrations and antiarrhythmic activity1

Ritonavir

Increased propafenone concentrations1 131 190 285 286 289

Use concomitantly with caution; reduce propafenone hydrochloride dosage1 131 190 285 286 289

Saquinavir

Increased propafenone concentrations1 131 190 285 286 289

Use concomitantly with caution; reduce propafenone hydrochloride dosage1 131 190 285 286 289

Sertraline

Increased propafenone concentrations1 131 190 285 286 289

Use concomitantly with caution; reduce propafenone hydrochloride dosage1 131 190 285 286 289

Theophylline

Increased serum theophylline concentrations and toxicity1 289

Venlafaxine

Increased venlafaxine concentrations1 289

Use concomitantly with caution; consider venlafaxine dosage reduction1 289

Warfarin

Increased plasma warfarin concentrations and corresponding PTs1 3 6 9 13 15 248 289

Monitor PTs or INRs;275 adjust warfarin dosage 1 3 9 13 248 289

Propafenone Hydrochloride Pharmacokinetics

Absorption

Bioavailability

Rapidly and almost completely absorbed following oral administration of conventional (immediate-release) tablets.1 3 15 17 33 40 67 68 133 136

Absolute bioavailability of conventional (immediate-release) tablets is 5–50%.33 174 180

Bioavailability of 325-mg extended-release capsules (given twice daily) similar to 150-mg conventional (immediate-release) tablets (given 3 times daily).289

Food

Food does not appear to affect bioavailability of conventional (immediate-release) tablets or extended-release capsules during multiple-dose administration.2 289

Special Populations

In patients with marked hepatic impairment, bioavailability of conventional (immediate-release) tablets is about 60–70%.1 2 178 289

Distribution

Extent

Rapidly distributed into lung, liver, and heart tissue.3 4 15

Propafenone crosses the placenta and is distributed into milk.3 64 72

Plasma or Serum Protein Binding

81–97% (mainly α1 acid glycoprotein).3 138 187 188 289

Special Populations

In patients with severe hepatic dysfunction, approximately 88% of propafenone is bound to plasma proteins.289

Elimination

Metabolism

Extensively metabolized by first-pass metabolism (hydroxylation) in the liver,1 33 132 133 136 via CYP2D6 to an active metabolite (5-hydroxypropafenone [5-OHP])1 131 190 289 and dealkylation via CYP1A2 and CYP3A4 to another active metabolite (N-depropylpropafenone [NDPP]).1 131 289

Elimination Route

Eliminated principally in feces via biliary excretion as metabolites and in urine or feces as unchanged drug (<1%).2 3 4 33 67 68 136

Half-life

Immediate-release tablets: Averages 1–3 hours (range: 2–10 hours).1 2 4 6 7 10 11 12 14 15 16 28 33 37 39 67 68 71 129 133 138 181 187

Special Populations

In patients with poor metabolizer phenotypes (approximately 5–10% of Caucasians), propafenone is metabolized principally via CYP3A4 and CYP1A2;1 131 CYP2D6 is subject to genetic polymorphism.1 131 190

Extensive metabolizers convert propafenone rapidly into 5-OHPand NDPP,1 15 33 37 41 68 70 129 130 131 136 189 190 289 while poor metabolizers convert it slowly to NDPP and 5-OHP usually not detectable.1 33 37 184 186 289

Poor metabolizers have increased plasma propafenone concentrations relative to individuals with the extensive-metabolizer phenotype3 13 15 33 40 67 69 130 and are more likely to experience β-blocking and adverse effects of the drug.13 36 39 129

In poor metabolizers, plasma elimination half-life and steady-state half-life average about 8-13 (range: 10–32 hours)1 2 3 4 6 10 16 33 37 39 40 68 133 and 17 hours, respectively; decreased clearance of the drug observed.33 67 175

In patients with moderate to severe hepatic impairment, half-life is about 9 hours.1 2 3 4 6 15 33 178

Stability

Storage

Oral

Conventional (immediate-release) Tablets

Tight, light-resistant containers at 25°C (may be exposed to 15-30°C).1 2 65 66

Extended-release Capsules

Tight containers at 25°C (may be exposed to 15-30°C).289

Actions

  • Membrane-stabilizing antiarrhythmic agent; exhibits local anesthetic effects.3 4 17 62 67 289

  • Combines with fast sodium channels within the myocardium and inhibits rapid sodium influx, which decreases the maximal rate of depolarization of phase 0 of the action potential.1 2 3 4 7 9 10 12 14 15 22 28 33 38 39 45 56 62 63 67 68 129 133 134 180 289 310

  • Combines with fast sodium channels in both their active and inactive state3 135 and inhibits recovery after repolarization in a time- and voltage-dependent manner, which is associated with subsequent dissociation of the drug from the sodium channels.1 2 4 6 7 10 11 12 13 14 15 16 18 19 33 38 39 62 67 68 90 134 135 168 180

  • Exhibits electrophysiologic effects characteristic of class IC antiarrhythmic agents, which slowly attach to and dissociate from transmembrane sodium channels.139 140 141 168

  • Produces dose-related decrease in intracardiac conduction within the His-Purkinje system, AV node, and intraventricular pathways.3 4 10 17 134 289

  • Produces dose-related increases in PR, QRS, AH, and HV intervals;1 3 6 7 62 96 129 133 134 180 289 at higher workload and heart rates, dose-related increases in QT interval occur.28 67 68

  • Increases effective refractory period (ERP) during ventricular pacing.3 27 67

  • Exhibits a dose-dependent negative inotropic effect.1 3 39 68 144 168 272 289

  • Exhibits β-adrenergic blocking activity.1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 18 22 24 25 26 27 33 36 37 38 39 42 45 46 47 56 62 63 67 68 129 133 137 289

Advice to Patients

  • Importance of taking propafenone in a consistent manner relative to food.6 9 128 256 272 273

  • Importance of not ingesting grapefruit juice concomitantly with propafenone.272 273

  • If a dose of extended-release capsules is missed, only administer the next scheduled dose; do not double next dose.289

  • Advise patients who self-administer conventional (immediate-release) tablets for conversion of paroxysmal atrial fibrillation to remain in a supine or sitting position until resolution of palpitations or for a period of ≥4 hours following the dose.290 309 Importance of informing clinician if palpitations do not resolve within 6–8 hours, if new symptoms (e.g., dyspnea, presyncope, syncope) occur, or a marked increase in heart rate develops.290

  • Advise patients to promptly report fever, sore throat, chills, or any other manifestation of infection.1 3 289

  • Importance of immediately informing clinician if excessive or prolonged diarrhea, sweating, vomiting, loss of appetite or thirst occurs.289 289

  • Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs and herbal supplements, as well as any concomitant illnesses.1 289

  • Importance of women informing clinician if they are or plan to become pregnant or plan to breast-feed.1 290

  • Importance of informing patients of other important precautionary information. (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Propafenone Hydrochloride

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules, extended-release

225 mg

RythmolSR

Reliant

325 mg

RythmolSR

Reliant

425 mg

RythmolSR

Reliant

Tablets, film-coated

150 mg*

Propafenone Hydrochloride Tablets

Ethex, Mutual, Qualitest, United Research, Watson

Rythmol (with povidone and propylene glycol; scored)

Reliant

225 mg*

Propafenone Hydrochloride Tablets

Ethex, Mutual, Qualitest, United Research, Watson

Rythmol (with povidone and propylene glycol; scored)

Reliant

300 mg*

Propafenone Hydrochloride Tablets

Ethex, Mutual, Qualitest, United Research, Watson

Rythmol (with povidone and propylene glycol; scored)

Reliant

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Propafenone HCl 150MG Tablets (WATSON LABS): 90/$115.99 or 270/$316.96

Propafenone HCl 225MG 12-hr Capsules (PAR): 30/$179.98 or 90/$509.96

Propafenone HCl 225MG Tablets (WATSON LABS): 90/$123.00 or 270/$363.97

Propafenone HCl 300MG Tablets (QUALITEST): 30/$70.99 or 90/$199.97

Propafenone HCl 325MG 12-hr Capsules (PAR): 30/$189.99 or 90/$539.98

Propafenone HCl 425MG 12-hr Capsules (PAR): 30/$199.98 or 90/$569.97

Rythmol 150MG Tablets (GLAXO SMITH KLINE): 30/$134.99 or 90/$389.97

Rythmol 225MG Tablets (GLAXO SMITH KLINE): 30/$170.99 or 90/$485.99

Rythmol SR 225MG 12-hr Capsules (GLAXO SMITH KLINE): 30/$189.99 or 90/$539.99

Rythmol SR 325MG 12-hr Capsules (GLAXO SMITH KLINE): 30/$247.78 or 90/$693.98

Rythmol SR 425MG 12-hr Capsules (GLAXO SMITH KLINE): 60/$512.97 or 180/$1,483.92

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions April 1, 2010. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Reliant Pharmaceuticals, Inc. Rythmol (propafenone hydrochloride) prescribing information. Liberty Corner, NJ; 2004 Sept.

2. Knoll Laboratories. Rythmol (propafenone hydrochloride) product monograph. Whippany, NJ; 1991 Jun.

3. Bryson HM, Palmer KJ, Langtry HD et al. Propafenone: a reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs. 1993; 45:85-130. [PubMed 7680987]

4. Harron DWG, Brogden RN. Propafenone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs. 1987; 34:617-47. [IDIS 237290] [PubMed 3322781]

5. Nestico PF, Morganroth J, Horowitz LN. New antiarrhythmic drugs. Drugs. 1988; 35:286-319. [IDIS 240386] [PubMed 3286214]

6. Funck-Brentano C, Kroemer HK, Lee JT et al. Propafenone. N Engl J Med. 1990; 322:518-25. [IDIS 263473] [PubMed 2405273]

7. Parker RB, McCollam PL, Bauman JL. Propafenone: a novel type Ic antiarrhythmic agent. DICP. 1989; 23:196-202. [IDIS 252242] [PubMed 2655298]

8. Anon. Propafenone for cardiac arrhythmias. Med Lett Drugs Ther. 1990; 32:37-8. [PubMed 2182990]

9. Chow MSS, Lebsack C, Hilleman D. Propafenone: a new antiarrhythmic agent. Clin Pharm. 1988; 7:869-77. [IDIS 248302] [PubMed 3061720]

10. Friedman PL, Antman EM, Singh BN. Propafenone: a new class IC antiarrhythmic drug for the management of ventricular arrhythmias. Hosp Formul. 1988; 23:531-536, 542.

11. Anon. A review of propafenone. Hosp Pharm. 1990; 25:177-8.

12. Nestico PF. Propafenone: a new antiarrhythmic drug. Am Fam Physician. 1988; 38:235-8. [PubMed 3046275]

13. Birgersdotter-Green U. Propafenone for cardiac arrhythmias. Am J Med Sci. 1992; 303:123-8. [IDIS 291472] [PubMed 1539611]

14. Brzozowski LA. Antiarrhythmic propafenone: improving patient outcomes. Dimen Crit Care Nurs. 1993; 12:116-22.

15. Shen EN. Propafenone: a promising new antiarrhythmic agent. Chest. 1990; 98:434-41. [IDIS 299333] [PubMed 2198142]

16. Somberg JC, Tepper D, Landau S. Propafenone: a new antiarrhythmic agent. Am Heart J. 1988; 115:1274-9. [IDIS 243253] [PubMed 3287873]

17. Hernandez M, Reder RF, Marinchak RA et al. Propafenone for malignant ventricular arrhythmia: an analysis of the literature. Am Heart J. 1991; 121:1178-84. [IDIS 280477] [PubMed 2008842]

18. Schlepper M. Propafenone, a review of its profile. Eur Heart J. 1987; 8(Suppl A):27-32. [PubMed 3556176]

19. Harrison DC. Antiarrhythmic drug classification: new science and practical applications. Am J Cardiol. 1985; 56:185-7. [PubMed 2409789]

20. Kowey PR, Stohler JL, Friehling TD et al. Propafenone in the treatment of patients with malignant ventricular tachyarrhythmias. Can J Cardiol. 1991; 7:175-80. [PubMed 2070286]

21. Cueni L, Podrid PJ. Propafenone therapy in patients with serious ventricular arrhythmia—noninvasive evaluation of efficacy. J Electrophysiol. 1987; 1:548-60.

22. Budde T, Borggrefe M, Podczeck A et al. Acute and long-term efficacy of oral propafenone in patients with ventricular tachyarrhythmias. J Cardiovasc Pharmacol. 1991; 18:254-60. [PubMed 1717787]

23. Geibel A, Meinertz T, Zehender M et al. Antiarrhythmic efficacy and tolerance of oral propafenone in patients with frequent ventricular arrhythmias: experience of a multicentre study. Eur Heart J. 1989; 10(Suppl E):81-7. [PubMed 2680506]

24. Singh BN, Kaplinsky E, Kirsten E et al et al. Effects of propafenone on ventricular arrhythmias: double-blind, parallel, randomized, placebo-controlled dose-ranging study. Am Heart J. 1988; 116:1542-51. [IDIS 248695] [PubMed 3057844]

25. Hammill SC, Sorenson PB, Wood DL et al. Propafenone for the treatment of refractory complex ventricular ectopic activity. Mayo Clin Proc. 1986; 61:98-103. [IDIS 211630] [PubMed 3945115]

26. Dhin H, Baker BJ, de Soyza N et al. Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricular arrhythmias: a 2-year experience. Am Heart J. 1988; 115:92-6. [IDIS 237759] [PubMed 3336989]

27. Kus T, Dubuc M, Lambert C et al. Efficacy of propafenone in preventing ventricular tachycardia: inverse correlation with rate-related prolongation of conduction time. J Am Coll Cardiol. 1990; 16:1229-37. [PubMed 2229772]

28. Connolly SJ, Kates RE, Lebsack CS et al. Clinical pharmacology of propafenone. Circulation. 1983; 68:589-96. [IDIS 175110] [PubMed 6872170]

29. Mason JW for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med. 1993; 329:452-8. [IDIS 318403] [PubMed 8332150]

30. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Eur Heart J. 1992; 13:1251-8. [PubMed 1396837]

31. Touboul P, Moleur P, Mathieu MP et al. A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. Eur Heart J. 1988; 9:1188-93. [PubMed 3234410]

32. Siebels J, Cappato R, Rüppel R et al and the CASH Investigators. Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol. 1993; 72:109-13F.

33. Hii JTY, Duff HJ, Burgess ED. Clinical pharmacokinetics of propafenone. Clin Pharmacokinet. 1991; 21:1-10. [PubMed 1914339]

34. Katoh T, Karagueuzian HS, Sugi K et al. Effects of propafenone on sinus nodal and ventricular automaticity: in vitro and in vivo correlation. Am Heart J. 1987; 113:941-52. [PubMed 3565244]

35. Klein RC, Huang SK, Marcus FI et al. Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine. Am Heart J. 1987; 114:551-8. [IDIS 233493] [PubMed 3630896]

36. Lee JT, Kroemer HK, Silberstein DJ et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med. 1990; 322:1764-8. [IDIS 267382] [PubMed 1971708]

37. Zoble RG, Kirsten EB, Brewington J and the Propafenone Research Group. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Clin Pharmacol Ther. 1989; 45:535-41. [IDIS 254748] [PubMed 2721109]

38. Dukes ID, Vaughan Williams EM. The multiple modes of action of propafenone. Eur Heart J. 1984; 5:115-25. [PubMed 6144546]

39. Barbey JT. Clinical pharmacology and β-blocking efficacy of propafenone. J Cardiovasc Pharmacol. 1991; 17(Suppl 6):S41-3. [PubMed 1723117]

40. Siddoway LA, Thompson KA, McAllister CB et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation. 1987; 75:785-91. [IDIS 229070] [PubMed 3829342]

41. Haefeli EW, Vozeh S, Ha HR et al. Comparison of the pharmacodynamic effects of intravenous and oral propafenone. Clin Pharmacol Ther. 1990; 48:245-54. [IDIS 271945] [PubMed 2401123]

42. Lombardi F, Torzillo D, Sandrone G et al. Beta-blocking effect of propafenone based on spectral analysis of heart rate variability. Am J Cardiol. 1992; 70:1028-34. [IDIS 303655] [PubMed 1357951]

43. Burgess E, Duff H, Wilkes P. Propafenone disposition in renal insufficiency and renal failure. J Clin Pharmacol. 1989; 29:112-3. [IDIS 252363] [PubMed 2715367]

44. Singlas E, Fillastre JP. Pharmacokinetics of newer drugs in patients with renal impairment (Part II). Clin Pharmacokinet. 1991; 20:389-410. [PubMed 1879096]

45. Philipsborn G, Gries J, Hofmann HP et al. Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone. Arzneimittelforschung. 1984; 34:1489-97. [PubMed 6543124]

46. McLeod AA, Stiles GL, Shand DG. Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. J Pharmacol Exp Ther. 1984; 228:461-6. [IDIS 181941] [PubMed 6141285]

47. Ravid S, Podrid PJ, Novrit B. Safety of long-term propafenone therapy for cardiac arrhythmia—experience with 774 patients. J Electrophysiol. 1987; 1:580-90.

48. Rankin AC. Adverse effects of antiarrhythmic drugs. Adv Drug React Toxicol Rev. 1992; 11:173-91.

49. Veale D, McComb JM, Gibson GJ. Propafenone. Lancet. 1990; 335:979. [IDIS 265366] [PubMed 1970054]

50. Mondardini A, Pasquino P, Bernardi P et al. Propafenone-induced liver injury: report of a case and review of the literature. Gastroenterology. 1993; 104:1524-6. [IDIS 314454] [PubMed 8482464]

51. Jack RA. A case of mania secondary to propafenone. J Clin Psychiatry. 1985; 46:104-5. [IDIS 197251] [PubMed 2579063]

52. Lecky BRF, Weir D, Chong E. Exacerbation of myasthenia by propafenone. J Neurol Neurosurg Psychiatry. 1991; 54:377. [PubMed 2056335]

53. Chua TP, Farrell T, Lipkin DP. Myoclonus associated with propafenone. BMJ. 1994; 308:113. [IDIS 325299] [PubMed 8298383]

54. Anon. Propaphenone: fatal dysrhythmias. WHO Drug Info. 1991; 5:9.

55. Latini R, Marchi S, Riva E et al. Distribution of propafenone and its active metabolite, 5-hydroxypropafenone, in human tissues. Am Heart J. 1987; 113:843-4. [IDIS 227350] [PubMed 3825881]

56. Lee P-K, Kerr CR, Vorderbrugge S et al. Symptomatic sinus node dysfunction associated with the use of propafenone. Am J Cardiol. 1988; 62:480-1. [IDIS 310835] [PubMed 3414526]

57. Lange H, Lampert S, St John Sutton M et al. Changes in cardiac output determined by continuous-wave doppler echocardiography during propafenone or mexiletine drug testing. Am J Cardiol. 1990; 65:458-62. [IDIS 298118] [PubMed 2305684]

58. Podrid PJ, Lampert S, Graboys TB et al. Aggravation of arrhythmia by antiarrhythmic drugs—incidence and predictors. Am J Cardiol. 1987; 59:38-44E. [PubMed 2949580]

59. Anon. Propafenone: an antiarrhythmic come in from the cold. Lancet. 1989; 2:1490-1. [PubMed 2574772]

60. Puech P, Gagnol JP. Class IC drugs: propafenone and flecainide. Cardiovasc Drugs Ther. 1990; 4:549-54. [PubMed 2125832]

61. Rehnqvist, Ericsson CG, Eriksson S et al. Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Med Scand. 1984; 216:525-30. [IDIS 196523] [PubMed 6395642]

62. Vaughn Williams EM. Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial. J Clin Pharmacol. 1991; 31:123-35. [IDIS 278432] [PubMed 1901320]

63. Spinler SA, Elder CA, Kindwall KE. Propafenone-induced liver injury. Ann Pharmacother. 1992; 26:926-8. [IDIS 299198] [PubMed 1354511]

64. Libardoni M, Piovan D, Busato E et al. Transfer of propafenone and 5-OH-propafenone to foetal plasma and maternal milk. Br J Clin Pharmacol. 1991; 32:527-8. [IDIS 289588] [PubMed 1958453]

65. Knoll Laboratories. Product information form for American hospital formulary service: Rythmol (propafenone hydrochloride) . Mount Olive, NJ; 1989 Dec 1.

66. The United States pharmacopeia, 23rd rev, and The national formulary, 18th ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1995:1313.

67. Faber TS, Camm AJ. The differentiation of propafenone from other class Ic agents, focusing on the effect on ventricular response rate attributable to its beta-blocking action. Eur J Clin Pharmacol. 1996; 51:199-208. [IDIS 380715] [PubMed 9010685]

68. Capucci A, Boriani G. Propafenone in the treatment of cardiac arrhythmias: a risk-benefit appraisal. Drug Saf. 1995; 12:55-72. [PubMed 7741984]

69. Lalka D, Griffith RK, Cronenberger CL. The hepatic first-pass metabolism of problematic drugs. J Clin Pharmacol. 1993; 33:657-69. [IDIS 318363] [PubMed 8366191]

70. Haefeli WE, Vozeh S, Ha HR et al. Concentration-effect relations of 5-hydroxypropafenone in normal subjects. Am J Cardiol. 1991; 67:1022-6. [IDIS 281730] [PubMed 2018005]

71. Vozeh S, Schmidlin O, Taeschner W. Pharmacokinetic drug data. Clin Pharmacokinet. 1988; :254-82. [IDIS 247363] [PubMed 3191648]

72. Brunozzi LT, Meniconi L, Chiocchi P et al. Propafenone in the treatment of chronic ventricular arrhythmias in a pregnant patient. Br J Clin Pharmacol. 1988; 26:489-90. [IDIS 247114] [PubMed 3191001]

73. Connolly S, Lebsack C, Winkle RA et al. Propafenone disposition kinetics in cardiac arrhythmia. Clin Pharmacol Ther. 1984; 36:163-8. [IDIS 188999] [PubMed 6744775]

74. Podrid PJ, Levine PA, Klein MP. Effect of age on antiarrhythmic drug efficacy and toxicity. Am J Cardiol. 1989; 63:735-9. [IDIS 304399] [PubMed 2646900]

75. Podrid PJ, Anderson JL, for the Propafenone Multicenter Study Group. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. Am J Cardiol. 1996; 78:430-4. [IDIS 372590] [PubMed 8752188]

76. Podczeck A, Frohner K, Hief C et al. Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation. Eur Heart J. 1991; 12:796-9. [PubMed 1889445]

77. Tisdale JE, Kluger J, Fisher JR et al. Efficacy of class 1C antiarrhythmic agents in patients with inducible ventricular tachycardia refractory to therapy with class 1A antiarrhythmic drugs. J Clin Pharmacol. 1993; 33:623-30. [IDIS 318357] [PubMed 8366187]

78. Podrid PJ, Lown B. Propafenone: a new agent for ventricular arrhythmia. J Am Coll Cardiol. 1984; 4:117-25. [PubMed 6376591]

79. Podrid PJ, Cytryn R, Lown B. Propafenone: noninvasive evaluation of efficacy. Am J Cardiol. 1984; 54:53-9D.

80. Brodsky MA, Allen BJ, Abate D et al. Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. Am Heart J. 1985; 110:794-9. [IDIS 207342] [PubMed 4050651]

81. Chilson DA, Heger JJ, Zipes DP et al. Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia. J Am Coll Cardiol. 1985; 5:1407-13. [PubMed 3889099]

82. Haffajee CI, Degon C, Huang SKS et al. Is programmed ventricular stimulation predictive of long term outcome in patients with malignant ventricular tachycardia taking propafenone? Circulation. 1989; 80 (Suppl II):II-652. Abstract No. 2589.

83. Yeung-Lai-Wah JA, Murdock CJ, Boone J et al. Propafenone-mexiletine combination for the treatment of sustained ventricular tachycardia. J Am Coll Cardiol. 1992; 20:547-51. [PubMed 1512331]

84. Reimold SC, Cantillon CO, Friedman PL et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1993; 71:558-63. [IDIS 310595] [PubMed 8438741]

85. Salerno DM, Granrud G, Sharkey P et al. A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes. Am J Cardiol. 1984; 53:77-83. [IDIS 179625] [PubMed 6362387]

86. Schamroth L, Myburgh DP, Schamroth CL et al. Oral propafenone in the suppression of chronic stable ventricular arrhythmias. Chest. 1985; 87:448-51. [IDIS 197964] [PubMed 3884286]

87. de Soyza N, Terry L, Murphy ML et al. Effect of propafenone in patients with stable ventricular arrhythmias. Am Heart J. 1984; 108:285-9. [IDIS 188369] [PubMed 6380253]

88. Channer KS. The drug treatment of atrial fibrillation. Br J Clin Pharmacol. 1991; 32:267-73. [IDIS 289202] [PubMed 1685662]

89. Ravi Kishore AG, Camm AJ. Guidelines for the use of propafenone in treating supraventricular arrhythmias. Drugs. 1995; 50:250-62. [PubMed 8521758]

90. Grant AO. Propafenone: an effective agent for the management of supraventricular arrhythmias. J Cardiovasc Electrophysiol. 1996; 7:353-64. [PubMed 8777484]

91. Cobbe SM. Drug therapy of supraventricular tachyarrhythmias—based on efficacy or futility? Eur Heart J. 1994; 15(Suppl A):22-6.

92. UK Propafenone PSVT Study Group. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation. 1995; 92:2550-7. [IDIS 358028] [PubMed 7586356]

93. Pritchett ELC, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: a randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. 1991; 114:539-44. [IDIS 279487] [PubMed 2001087]

94. Allen BJ, Brodsky MA, Doria R et al. Oral propafenone therapy for patients with paroxysmal supraventricular tachyarrhythmia. Chest. 1988; 94:853-4. [IDIS 246643] [PubMed 3168580]

95. Shen EN, Keung E, Huycke E et al. Intravenous propafenone for termination of reentrant supraventricular tachycardia: a placebo-controlled, randomized, double-blind, crossover study. Ann Intern Med. 1986; 105:655-61. [IDIS 222899] [PubMed 3767146]

96. Dubuc M, Kus T, Campa MA et al. Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome. Am Heart J. 1989; 117:370-6. [IDIS 251856] [PubMed 2644795]

97. Ludmer PL, McGowan NE, Antman EM et al. Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. J Am Coll Cardiol. 1987; 9:1357-63. [PubMed 3294970]

98. Boahene KA, Klein GJ, Yee R et al. Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. J Am Coll Cardiol. 1990; 16:1408-14. [PubMed 2229793]

99. Antman EM, Beamer AD, Cantillon C et al. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol. 1988; 12:1005-11. [PubMed 3417972]

100. Hammill SC, McLaran CJ, Wood DL et al. Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia. J Am Coll Cardiol. 1987; 9:1364-8. [PubMed 3584724]

101. Capucci A, Boriani G, Botto GL et al. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol. 1994; 74: 503-5. [IDIS 334533] [PubMed 8059737]

102. Lip GYH, Watson RDS, Singh SP. Drugs for atrial fibrillation. BMJ. 1995; 311:1631-4. [IDIS 357847] [PubMed 8555811]

103. Suttorp MJ, Kingma JH, Jessurun ER et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol. 1990; 16:1722-7. [PubMed 2123909]

104. Bianconi L, Boccadamo R, Pappalardo A et al. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol. 1989; 64:335-8. [PubMed 2667304]

105. Connolly SJ, Hoffert DL. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol. 1989; 63:817-9. [IDIS 252747] [PubMed 2648787]

106. Vita JA, Friedman PL, Cantillon C et al. Efficacy of intravenous propafenone for the acute management of atrial fibrillation. Am J Cardiol. 1989; 63:1275-8. [IDIS 255514] [PubMed 2711997]

107. Porterfield JG, Porterfield LM. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol. 1989; 63:114-6. [IDIS 253901] [PubMed 2909141]

108. Hammill SC, Wood DL, Gersh BJ et al. Propafenone for paroxysmal atrial fibrillation. Am J Cardiol. 1988; 61:473-4. [IDIS 239088] [PubMed 3341233]

109. Boriani G, Biffi M, Capucci A et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease: a randomized, controlled trial. Ann Intern Med. 1997; 126:621-5. [IDIS 383634] [PubMed 9103129]

110. Stroobandt R, Stiels B, Hoebrechts R et al. Propafenone for conversion and prophylaxis of atrial fibrillation. Am J Cardiol. 1997; 79:418-23. [IDIS 382730] [PubMed 9052343]

111. Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med. 1997; 336:1429-34. [IDIS 385154] [PubMed 9145681]

112. Weiner B. Second generation antidysrhythmic agents. Crit Care Nurs Clin North Am. 1989; 1:417-22. [PubMed 2684236]

113. Hussar DA. New drugs of 1990. Am Pharm. 1991; NS31:54-. [PubMed 2028913]

114. Hopkins SJ. Propafenone. Drugs Today. 1989; 25:573-6.

115. Köppel C, Oberdisse U, Heinemeyer G. Clinical course and outcome in class IC antiarrhythmic overdose. Clin Toxicol. 1990; 28:433-44.

116. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med. 1994; 331:785-91. [IDIS 335149] [PubMed 8065408]

117. Morganroth J, Bigger JT Jr. Pharmacologic management of ventricular arrhythmias after the cardiac arrhythmia suppression trial. Am J Cardiol. 1990; 65:1497-503. [IDIS 267779] [PubMed 2091621]

118. Tisdale JE, Webb CR. Are antiarrhythmic drugs obsolete? Clin Pharm. 1992; 11:714-26.

119. Murdock CJ, Kyles AE, Yeung-Lai-Wah JA et al. Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol. 1990; 66:755-7. [IDIS 272561] [PubMed 2399896]

120. Podrid PJ. Aggravation of ventricular arrhythmia: a drug-induced complication. Drugs. 1985; 29(Suppl 4):33-44. [IDIS 200453] [PubMed 3924550]

121. Anon. Drugs that cause psychiatric symptoms. Med Lett Drugs Ther. 1993; 35:65-70. [PubMed 8321161]

122. Feld GK, Nademanee K, Singh BN et al. Hemodynamic and electrophysiologic effects of combined infusion of lidocaine and propafenone in humans. J Clin Pharmacol. 1987; 27:52-9. [IDIS 225249] [PubMed 3680555]

123. Funck-Brentano C, Kroemer HK, Pavlou H et al. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol. 1989; 27:435-44. [IDIS 254183] [PubMed 2719900]

124. Bigot MC, Debruyne D, Bonnefoy L et al. Serum digoxin levels related to plasma propafenone levels during concomitant treatment. J Clin Pharmacol. 1991; 31:521-6. [IDIS 284738] [PubMed 1880217]

125. Calvo MV, Martin-Suarez A, Luengo CM et al. Interaction between digoxin and propafenone. Ther Drug Monit. 1989; 11:10-5. [IDIS 248983] [PubMed 2911842]

126. Latini R, Barbieri E, Castello C et al. Propafenone and 5-hydroxypropafenone concentrations in the right atrium of patients undergoing heart surgery. Am Heart J. 1989; 117:497-8. [IDIS 251859] [PubMed 2916423]

127. Lee BL, Dohrmann ML. Theophylline toxicity after propafenone treatment: evidence for drug interaction. Clin Pharmacol Ther. 1992; 51:353-5. [IDIS 293947] [PubMed 1544292]

128. Axelson JE, Chan GL Y, Kirsten EB et al. Food increases the bioavailability of propafenone. Br J Clin Pharmacol. 1987; 23:735-41. [IDIS 231698] [PubMed 3606933]

129. Chimienti M, Cullen MT Jr, Casadei G, for the Flecainide and Propafenone Italian Study (FAPIS) Investigators. Am J Cardiol. 1996; 77:60-5A.

130. Capucci A, Boriani G, Marchesini B et al. Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. Cardiovasc Drugs Ther. 1990; 4:281-7. [PubMed 2285622]

131. Botsch S, Gautier JP, Beaune P et al. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993; 43:120-6. [PubMed 8423765]

132. Cobbe SM. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachyarrhythmias. J Am Coll Cardiol. 1994; Feb:251A.

133. Reimold SC, Antman EM. Meta-analysis of the efficacy of propafenone for treating supraventricular arrhythmias. Circulation Suppl. 1996; 94:I-665.

134. Delgado C, Tamargo J, Tejerina T. Electrophysiological effects of propafenone in untreated and propafenone-pretreated guinea-pig atrial and ventricular muscle fibres. Br J Pharmacol. 1985; 86:765-75. [PubMed 4075015]

135. Honjo H, Watanabe T, Kamiya K et al. Effects of propafenone on electrical and mechanical activities of single ventricluar myocytes isolated from guinea-pig hearts. Br J Pharmacol. 1989; 97:731-8. [PubMed 2758239]

136. Hege HG, Hollmann M, Kaumeier S et al. The metabolic fate of2 H-labelled propafenone in man. Eur J Drug Metab Pharmacokinet. 1984; 9:41-55. [PubMed 6714269]

137. Ledda F, Mantelli L, Manzini S et al. Electrophysiological and antiarrhythmic properties of propafenon in isolated cardiac preparations. J Cardiovasc Pharmacol. 1981; 3:1162-73. [PubMed 6173515]

138. Hollmann M, Brode E, Hotz D et al. Investigations on the pharmacokinetics of propafenone in man. Arzneimittelforschung. 1983; 33:763-70. [PubMed 6683556]

139. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984; 24:129-47. [IDIS 186026] [PubMed 6144698]

140. Maisel WH, Kuntz KM, Reimold SC et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med. 1997; 127:281-4. [IDIS 390176] [PubMed 9265427]

141. Campbell TJ. Kinetics of onset of rate-dependent effects of class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res. 1983; 17:344-52. [PubMed 6883410]

142. Connolly SJ, Kates RE, Lebsack CS et al. Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol. 1983; 52:1208-13. [IDIS 179054] [PubMed 6359849]

143. Prystowsky EN, Heger JJ, Chilson DA et al. Antiarrhythmic and electrophysiologic effects of oral propafenone. Am J Cardiol. 1984; 54:26-8D.

144. Stoschitzky K, Klein W, Stark G et al. Different stereoselective effects of (R)- and (S)-propafenone: clinical pharmacologic, electrophysiologic, and radioligand binding studies. Clin Pharmacol Ther. 1990; 47:740-6. [IDIS 268714] [PubMed 2162749]

145. Seipel L, Hoffmeister HM. Hemodynamic effects of antiarrhythmic drugs: negative inotropy versus influence on peripheral circulation. Am J Cardiol. 1989; 64:37-40J. [PubMed 2741812]

146. Musto B, D’Onofrio A, Cavallaro C et al. Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia. Circulation. 1988; 78:863-9. [IDIS 247619] [PubMed 3168194]

147. Baker BJ, de Soyza N, Boyd CM et al. Effects of propafenone on left ventricular function. Circulation. 1982; 67:II-267.

148. Ruskin JN. The Cardiac Arrhythmia Suppression Trial (CAST). N Engl J Med. 1989; 321:386-8. [IDIS 257833] [PubMed 2501683]

149. The Cardiac Arrhythmia Suppression Trial (CAST) investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989; 321:406-12. [IDIS 257848] [PubMed 2473403]

150. Pratt CM, Brater DC, Harrell FE Jr et al. Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial. Am J Cardiol. 1990; 65:103-5. [PubMed 1688479]

151. Garratt C, Ward DE, Camm AJ. Lessons from the cardiac arrhythmia suppression trial. BMJ. 1989; 299:805-6. [IDIS 259519] [PubMed 2510839]

152. Anon. Restrictions on use of flecainide, encainide. FDA Drug Bull. 1989; 16.

153. Anon. Flecainide and CAST. Lancet. 1989; 2:481-2. [PubMed 2570188]

154. Ward D, Garratt C, Camm AJ. Cardiac arrhythmia suppression trial and flecainide. Lancet. 1989; 1:1267-8. [IDIS 255586] [PubMed 2566810]

155. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324:781-8. [IDIS 279004] [PubMed 1900101]

156. Epstein AE, Hallstrom AP, Rogers WJ et al. mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA. 1993; 270:2451-5. [IDIS 322639] [PubMed 8230622]

157. Vlay SC. Lessons from the past and reflections on the Cardiac Arrhythmia Suppression trial. Am J Cardiol. 1990; 65:112-3. [PubMed 1688480]

158. Van Gelder IC, Brugemann J, Crijns HJGM. Pharmacological management of arrhythmias in the elderly. Drugs Aging. 1997; 11:96-110. [PubMed 9259173]

159. Anon. CAST deaths revealed. Lancet. 1991; 337:969.

160. Botto GL, Bonini W, Broffoni T et al. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? Pacing Clin Electrophysiol. 1996; 19(11 Part 2):1939-43.

161. Robson RH. Indications for flecainide. Lancet. 1989; 2:113.

162. Luedtke SA, Kuhn RJ, McCaffrey FM. Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry. Ann Pharmacother. 1997; 31:1227-43. [IDIS 392976] [PubMed 9337449]

163. Coyle JD, Schaal SF. An interim perspective on the removal of encainide and flecainide from the Cardiac Arrhythmia Suppression Trial. DICP. 1989; 23:478-9. [IDIS 254807] [PubMed 2500783]

164. Food and Drug Administration. FDA Cardio-renal Advisory Committee will review CAST study. FDC Rep. 1989(Aug 14):3-4.

165. Luedtke SA, Kuhn RJ, McCaffrey FM. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia. Ann Pharmacother. 1997; 31:1347-59. [IDIS 395069] [PubMed 9391691]

166. Nightingale SL. Flecainide and encainide not to be used in non-life-threatening arrhythmias. JAMA. 1989; 261:3368. [PubMed 2498536]

167. Eagleton G. Dear doctor letter regarding appropriate uses of Tambocor. St. Paul, MN: 3M Riker; 1989 May.

168. Caron J, Libersa C. Adverse effects of class I antiarrhythmic drugs. Drug Saf. 1997; 17:8-36. [PubMed 9258628]

169. Flaker GC, Blackshear JL, McBride R et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol. 1992; 20:527-32. [PubMed 1512329]

170. Coplen SE, Antman EM, Berlin JA et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation. 1990; 82:1106-16. [IDIS 272784] [PubMed 2144796]

171. Baker BJ, Brodsky MA, Dinh H et al. Hemodynamic effect of propafenone and the experience in patients with congestive heart failure. J Electrophysiol. 1987; 1:527-35.

172. Krenzer M. (Food and Drug Administration, Drug Information Branch): Personal communication; 1997 Sep 22.

173. Hill MR, Gotz VP, Harman E et al. Evaluation of the asthmogenicity of propafenone, a new antiarrhythmic drug: comparison of spirometry with methacholine challenge. Chest. 1986; 90:698-702. [IDIS 227764] [PubMed 3533454]

174. Vozeh S, Haefeli W, Ha HR et al. Nonlinear kinetics of propafenone metabolites in healthy man. Eur J Clin Pharmacol. 1990; 38:509-13. [IDIS 267730] [PubMed 2379537]

175. Kroemer HK, Funck-Brentano C, Silberstein DJ et al. Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation. 1989; 79:1068-76. [IDIS 254395] [PubMed 2713973]

176. Kroemer HK, Fromm MF, Eichelbaum M. Stereoselectivity in drug metabolism and action: effects of enzyme inhibition and induction. Ther Drug Monit. 1996; 18:388-92. [IDIS 372907] [PubMed 8857556]

177. Kroemer HK, Fromm MF, Bühl K et al. An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Circulation. 1994; 89:2396-400. [IDIS 329543] [PubMed 7910120]

178. Lee JT, Yee YG, Dorian P et al. Influence of hepatic dysfunction on the pharmacokinetics of propafenone. J Clin Pharmacol. 1987; 27:384-9. [IDIS 241743] [PubMed 3693582]

179. Fromm MF, Botsch S, Heinkele G et al. Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites. Eur J Clin Pharmacol. 1995; 48:279-83. [IDIS 352303] [PubMed 7589055]

180. Seipel L, Breithardt G. Propafenone—a new antiarrhythmic drug. Eur Heart J. 1980; 1:309-13. [PubMed 7023945]

181. Giani P, Landolina M, Giudici V et al. Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration. Eur J Clin Pharmacol. 1988; 34:187-94. [IDIS 240807] [PubMed 3383990]

182. Frabetti L, Marchesini B, Capucci A et al. Antiarrhythmic efficacy of propafenone: evaluation of effective plasma levels following single and multiple doses. Eur J Clin Pharmacol. 1986; 30:665-71. [IDIS 221607] [PubMed 2429844]

183. Golzari H, Cebul RD, Bahler RC. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med. 1996; 125:311-23. [IDIS 370040] [PubMed 8678396]

184. Kates RE, Yee YG, Winkle RA. Metabolite cumulation during chronic propafenone dosing in arrhythmia. Clin Pharmacol Ther. 1985; 37:610-4. [IDIS 201887] [PubMed 4006362]

185. Reviewers’ comments (personal observations) on encainide 24:04.

186. Steurer G, Weber H, Schmidinger H et al. Plasma propafenone concentration in the evaluation of anti-arrhythmic efficacy. Eur Heart J. 1991; 12:526-32. [PubMed 2065687]

187. O’Rourke DJ, Palac RT, Holzberger PT et al. Propafenone-induced drug fever in the absence of agranulocytosis. Clin Cardiol. 1997; 20:662-4. [PubMed 9220185]

188. Chan GLY, Axelson JE, Price JDE et al. In vitro protein binding of propafenone in normal and uraemic human sera. Eur J Clin Pharmacol. 1989; 36:495-9. [PubMed 2753068]

189. Malfatto G, Zaza A, Forster M et al. Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone. J Pharmacol Exp Ther. 1988; 246:419-26. [PubMed 3404440]

190. Kroemer HK, Mikus G, Kronbach T et al. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther. 1989; 45:28-33. [PubMed 2910635]

191. Brode E, Müller-Peltzer H, Hollmann M. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man. Methods Find Exp Clin Pharmacol. 1988; 10:717-27. [PubMed 3221745]

192. Kroemer HK, Fischer C, Meese CO et al. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism. Mol Pharmacol. 1991; 40:135-42. [PubMed 1857335]

193. McHugh TP, Perina DG. Propafenone ingestion. Ann Emer Med. 1987; 16:437-40.

194. Knoll Pharmaceutical Company, Mount Olive, NJ: Personal communication.

195. Azpitarte J, Alvarez M, Baún O et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Eur Heart J. 1997; 18:1649-54. [PubMed 9347277]

196. Botto GL, Capucci A, Bonini W et al. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. Intl J Cardiol. 1997; 58:55-61.

197. Connolly SJ, Mulji AS, Hoffert DL et al. Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. J Am Coll Cardiol. 1987; 10:1145-8. [PubMed 3499456]

198. Merrick AF, Odom NJ, Keenan DJM et al. Comparison of propafenone to atenolol for the prophylaxis of postcardiotomy supraventricular tachyarrhythmias: a prospective trial. Eur J Cardiothorac Surg. 1995; 9:146-9. [PubMed 7786531]

199. Weiner P, Ganam R, Ganem R et al. Clinical course of recent-onsent atrial fibrillation treated with oral propafenone. Chest. 1994; 105:1013-6. [IDIS 328126] [PubMed 8162718]

200. Aliot E, Denjoy I, and the Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. Am J Cardiol. 1996; 77:66A-71. [IDIS 363431] [PubMed 8607394]

201. Crijns HJGM, Gosselink ATM, Lie KI et al. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. Cardiovasc Drugs Ther. 1996; 10:145-52. [PubMed 8842506]

202. Lee SH, Chen SA, Chiang CE et al. Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. J Intern Med. 1996; 239:253-60. [IDIS 364574] [PubMed 8772625]

203. Bianconi L, Mennuni M, Lukic V et al. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol. 1996; 28:700-6. [IDIS 373073] [PubMed 8772759]

204. Sager PT. Atrial fibrillation: antiarrhythmic therapy versus rate control with antithrombotic therapy. Am J Cardiol. 1997; 80:74G-81. [IDIS 396234] [PubMed 9354414]

205. Lee SH, Chen SA, Tai CT et al. Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol. 1997; 79:905-8. [IDIS 385106] [PubMed 9104904]

206. Antman EM, Beamer AD, Cantillon C et al. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol. 1990; 15:698-707. [PubMed 2303641]

207. Fresco C, Proclemer A, Pavan A et al et al. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Clin Cardiol. 1996; 19:409-12. [PubMed 8723601]

208. Boriani G, Capucci A, Lenzi T et al. Propafenone for conversion of recent-onset atrial fibrillation: a controlled comparison between oral loading dose and intravenous administration. Chest. 1995; 108:355-8. [IDIS 351624] [PubMed 7634866]

209. Bellandi F, Dabizzi RP, Cantini F et al. Intravenous propafenone: efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation—a single-blind placebo-controlled study. Cardiovasc Drugs Ther. 1996; 10:153-7. [PubMed 8842507]

210. Zehender M, Hohnloser S, Geibel A et al. Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms. Br Heart J. 1992; 67:491-7. [IDIS 298422] [PubMed 1622701]

211. Jung F, DiMarco JP. Treatment strategies for atrial fibrillation. Am J Med. 1998; 104:272-86. [IDIS 405394] [PubMed 9552091]

212. Reimer A, Paul T, Kallfelz HC. Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias. Am J Cardiol. 1991; 68:741-4. [IDIS 288997] [PubMed 1892080]

213. Janousek J, Paul T, Reimer A et al. Usefulness of propafenone for supraventricular arrhythmias in infants and children. Am J Cardiol. 1993; 72:294-300. [IDIS 319009] [PubMed 8342507]

214. Paul T, Janousek J. New antiarrhythmic drugs in pediatric use: propafenone. Pediatr Cardiol. 1994; 15:190-7. [PubMed 7991437]

215. Olm M, Munne P, Jimenez MJ. Severe reactive airways disease induced by propafenone. Chest. 1989; 95:1366-7. [IDIS 255846] [PubMed 2721285]

216. Guccione P, Drago F, Di Donato RM et al. Oral propafenone therapy for children with arrhythmias: efficacy and adverse effects in midterm follow-up. Am Heart J. 1991; 122:1022-7. [IDIS 290153] [PubMed 1927853]

217. Paul T, Reimer A, Janousek J et al. Efficacy and safety of propafenone in congenital junctional ectopic tachycardia. J Am Coll Cardiol. 1992; 20:911-4. [PubMed 1527301]

218. Beaufort-Krol GCM, Bink-Boelkens MTE. Oral propafenone as treatment for incessant supraventricular and ventricular tachycardia in children. Am J Cardiol. 1993; 72:1213-4. [IDIS 322186] [PubMed 8237821]

219. Vignati G, Mauri L, Figini A. The use of propafenone in the treatment of tachyarrhythmias in children. Eur Heart J. 1993; 14:546-50. [PubMed 8472721]

220. Fish FA, Mehta AV, Johns JA. Characteristics and management of chaotic atrial tachycardia of infancy. Am J Cardiol. 1996; 78:1052-5. [PubMed 8916490]

221. Miwa LJ, Jolson HM. Propafenone associated agranulocytosis. PACE. 1992; 15:387-90. [PubMed 1374882]

222. Jones RJ, Brace SR, Vander Tuin EL. Probable propafenone-induced transient global amnesia. Ann Pharmacother. 1995; 29:586-90. [IDIS 349729] [PubMed 7663030]

223. Galasso PJ, Stanton MS, Vogel H. Propafenone-induced peripheral neuropathy. Mayo Clin Proc. 1995; 70:469-72. [IDIS 346134] [PubMed 7731257]

224. Sulke AN, Holt P, Sowton GE. Acceleration of conduction within an accessory pathway with propafenone. Int J Cardiol. 1990; 28:105-7. [PubMed 2365521]

225. Schüppel R, Probst M. Acute cholestatic hepatitis and the sudden rise of the pacing threshold 5 weeks after VVI-pacemaker implantation. J Intern Med. 1994; 236:353-6. [IDIS 335352] [PubMed 8077895]

226. Mörike K, Magadum S, Mettang T et al. Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy. J Intern Med. 1995; 238:469-72. [IDIS 358617] [PubMed 7595187]

227. Hii JTY, Wyse DG, Gillis AM et al. Propafenone-induced torsade de pointes: cross-reactivity with quinidine. PACE. 1991; 14:1568-70. [PubMed 1721143]

228. Scanu P, Grollier G, Guilleman D et al. Malignant ventricular tachycardia during propafenone treatment in a child with junctional automatic tachycardia: effectiveness of intravenous molar sodium lactate. PACE. 1991; 14:783-6. [PubMed 1712954]

229. Montefoschi N, Boccadamo R. Propafenone induced acute variation of chronic atrial pacing threshold: a case report. PACE. 1990; 13:480-3. [PubMed 1692131]

230. Reimold SC. Avoiding drug problems: the safety of drugs for supraventricular tachycardia. Eur Heart J. 1997; 18(Suppl C):C40-4. [PubMed 9152674]

231. Maisel WH, Kuntz KM, Reimold SC et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med. 1997; 127:281-4. [IDIS 390176] [PubMed 9265427]

232. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med. 1992; 117:141-50. [IDIS 299038] [PubMed 1605429]

233. Chimienti M, Cullen MT Jr, Casadei G et al. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias: report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Eur Heart J. 1995; 16:1943-51. [PubMed 8682031]

234. Moroe K, Annoura M, Matsuo K et al. Proarrhythmic effects of class Ic drugs. Clin Ther. 1993; 15:559-66. [PubMed 8364947]

235. Morganroth J. Proarrhythmic effects of antiarrhythmic drugs: evolving concepts. Am Heart J. 1992; 123:1137-9. [IDIS 293753] [PubMed 1553883]

236. Santinelli V, Arnese M, Oppo I et al. Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function. Chest. 1993; 103:1068-73. [IDIS 312611] [PubMed 8131440]

237. Pratt CM, Moyé LA. The cardiac arrhythmia suppression trial: casting suppression in a different light. Circulation. 1995; 91:245-7. [PubMed 7805210]

238. Kerns W II, English B, Ford M. Propafenone overdose. Ann Emerg Med. 1994; 24:98-103. [IDIS 332250] [PubMed 8010557]

239. Maxeiner H, Klug E. Lethal suicidal intoxication with propafenone, after a history of self-inflicted injuries. Forensic Sci Int. 1997; 89:27-32. [PubMed 9306661]

240. Chouty F, Funck-Brentano C, Leenhardt A et al. Intravenous sodium lactate as a treatment of class I anti-arrhythmic agents overdose. Circulation. 1989; 80(Suppl II):II-430.

241. Mörike KE, Roden DM. Quinidine-enhanced β-blockade during treatment with propafenone in extensive metabolizer human subjects. Clin Pharmacol Ther. 1994; 55:28-34. [IDIS 325100] [PubMed 7905369]

242. Libersa C, Caron J, Broly F et al. Interaction of propafenone and mexiletine. J Am Coll Cardiol. 1993; 22:2061. [PubMed 8245368]

243. Kerr CR, Yeung-Lai-Wah J. Interaction of propafenone and mexiletine. J Am Coll Cardiol. 1993; 22:2061-2. [PubMed 8245368]

244. Ujhelyi MR, O’Rangers EA, Fan C et al. The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. Clin Pharmacol Ther. 1993; 53:38-48. [IDIS 308973] [PubMed 8422740]

245. Zalzstein E, Koren G, Bryson SM et al. Interaction between digoxin and propafenone in children. J Pediatr. 1990; 116:310-2. [IDIS 266711] [PubMed 2299507]

246. Kowey PR, Kirsten EB, Fu CHJ et al. Interaction between propranolol and propafenone in healthy volunteers. J Clin Pharmacol. 1989; 29:512-7. [IDIS 257057] [PubMed 2754020]

247. Wagner F, Kalusche D, Trenk D et al. Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol. 1987; 24:213-20. [IDIS 233408] [PubMed 3620296]

248. Kates RE, Yee YG, Kirsten EB. Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther. 1987; 42:305-11. [IDIS 234442] [PubMed 3621785]

249. Pritchett ELC, Smith WM, Kirsten EB. Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. J Clin Pharmacol. 1988; 28:619-24. [IDIS 244647] [PubMed 3063727]

250. Spes CH, Angermann CE, Horn K et al. Ciclosporin-propafenone interaction. Klin Wochenschr. 1990; 68:872. [PubMed 2214612]

251. Katz MR. Raised serum levels of desipramine with the antiarrhythmic propafenone. J Clin Psychiatry. 1991; 52:432-3. [IDIS 289803] [PubMed 1938981]

252. Spinler SA, Gammaitoni A, Charland SL et al. Propafenone-theophylline interaction. Pharmacotherapy. 1993; 13:68-71. [IDIS 311794] [PubMed 8437970]

253. Ahmad S. Metoprolol-induced delirium perpetuated by propafenone. Am Fam Physician. 1991; 44:1142-4. [PubMed 1927831]

254. Zipes DP. A consideration of antiarrhythmic therapy. Circulation. 1985; 72:949-56. [IDIS 209286] [PubMed 3930087]

255. Coumel P, Chouty F, Slama R. Logic and empiricism in the selection of antiarrhythmic agents: the role of drug combinations. Drugs. 1985; 29(Suppl 4):68-76. [IDIS 200457] [PubMed 4006782]

256. Koytchev R, Alken RG, Mayer O et al. Influence of food on the bioavailability and some pharmacokinetic parameters of diprafenone–a novel antiarrhythmic agent. Eur J Clin Pharmacol. 1996; 50:315-9. [IDIS 369903] [PubMed 8803526]

257. Spence JD. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Pharmacol Ther. 1997; 61:395-400. (IDIS 385684)

258. Shader RI, Greenblatt DJ. Fruit juices and pharmacology. J Clin Psychopharmacol. 1997; 17:245-6. [IDIS 390482] [PubMed 9241001]

259. Roller L. Drugs and grapefruit juice. Clin Pharmacol Ther. 1998; 63:87. [IDIS 398865] [PubMed 9465845]

260. Spence JD. Drugs and grapefruit juice. Clin Pharmacol Ther. 1998; 63:87-8. [IDIS 398865] [PubMed 9465845]

261. Weiner M. Informing the public. Clin Pharmacol Ther. 1997; 62:578-9. [IDIS 398092] [PubMed 9390116]

262. Spence JD. Informing the public. Clin Pharmacol Ther. 1997; 62:579. [IDIS 398093] [PubMed 9390117]

263. Boucher M, Chassaing C, Hamel JD et al. Cardiac electrophysiological effects of propafenone and its 5-hydroxylated metabolite in the conscious dog. Eur J Pharmacol. 1996; 315:171-7. [PubMed 8960881]

264. Podrid PJ. Safety and toxicity of antiarrhythmic drug therapy: benefit versus risk. J Cardiovasc Pharmacol. 1991; 17(Suppl 6):S65-73. [PubMed 1723122]

265. Hapke HJ, Prigge E. Pharmacology of 2′-[2-hydroxy-3-(propylamino)-propoxy]-3-phenylpropiophenone (Propafenone, SA 79)-hydrochloride. Arzneimittelforschung. 1976; 26:1849-57. [PubMed 1037204]

266. Burgess ED, Duff HJ. Hemodialysis removal of propafenone. Pharmacotherapy. 1989; 9:331-3. [IDIS 389383] [PubMed 2813154]

267. Prystowsky EN, Benson W Jr, Fuster V et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation. 1996; 93:1262-77. [IDIS 364782] [PubMed 8653857]

268. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med. 1989; 111:107-11. [IDIS 257099] [PubMed 2500880]

269. Kowey PR, Marinchak RA, Rials SJ et al. Acute treatment of atrial fibrillation. Am J Cardiol. 1998; 81:16C-22C. [IDIS 404075] [PubMed 9525568]

270. Kennedy HL, Whitlock JA, Sprague MK et al. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med. 1985; 312:193-7. [PubMed 2578212]

271. Van Gelder IC, Brugemann J, Crijns HJGM. Current treatment recommendations in antiarrhythmic therapy. Drugs. 1998; 55:331-46. [PubMed 9530541]

272. Reviewers’ comments (personal observations).

273. Knoll Pharmaceutical Company, Mt. Olive, NJ: Personal communication.

274. Tartini R, Kappenberger L, Steinbrunn W et al. Gefahrliche Interaktionen zwischen Amiodaron und Antiarrhythmika der Klasse I. (German; with English abstract.) Schweiz Med Wochenschr. 1982; 112:1585-7. (amiodarone ref 264)

275. Ansell JE, Buttaro ML, Voltis Thomas O et al et al. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Ann Pharmacother. 1997; 31:604-15. [IDIS 384308] [PubMed 9161658]

276. Woodland C, Verjee Z, Giesbrecht E et al. The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers. J Pharmacol Exp Ther. 1997; 283: 39-45. [PubMed 9336306]

277. Woodland C, Ito S, Koren G. A model for the prediction of digoxin-drug interactions at the renal tubular cell level. Ther Drug Monit. 1998; 20:134-8. [PubMed 9558126]

278. Nolan PE Jr, Marcus FI, Erstad BL et al. Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects. J Clin Pharmacol. 1989; 29:46-52. [IDIS 253182] [PubMed 2708548]

279. Belz GG, Doering W, Munkes R et al. Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin Pharmacol Ther. 1983; 33:410-7. [IDIS 169079] [PubMed 6831819]

280. Hii JT, Duff HJ, Burgess ED. Clinical pharmacokinetics of propafenone. Clin Pharmacokinet. 1991; 21:1-10. [PubMed 1914339]

281. Koytchev R, Alken RG,; Mayer O. Effect of diprafenone on the pharmacokinetics of digoxin. Eur J Clin Pharmacol. 1996; 50:97-100. [IDIS 367590] [PubMed 8739818]

282. Palumbo E, Svetoni N, Casini M et al. [Digoxin-propafenone interaction: values and limitations of plasma determination of the 2 drugs. Anti-arrhythmia effectiveness of propafenone]. G Ital Cardiol. 1986; 16:855-62. [PubMed 3817368]

283. Calvo MV, Martin-Suarez A, Martin Luengo C et al. Interaction between digoxin and propafenone. Ther Drug Monit. 1989; 11:10-5. [IDIS 248983] [PubMed 2911842]

284. Hodges M, Salerno D, Granrud G. Double-blind placebo-controlled evaluation of propafenone in suppressing ventricular etopic activity. Am J Cardiol. 1984; 54:45D-50D. [IDIS 193815] [PubMed 6388303]

285. Piscitelli SC, Flexner C, Minor JR et al. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996; 23:685-93. [IDIS 375126] [PubMed 8909827]

286. Abbott Laboratories. Norvir (ritonavir) capsules and oral solution prescribing information. North Chicago, IL; 1997 Mar.

287. Marcus FI. Drug interactions with amiodarone. Am Heart J. 1983; 106(4 Part 2):924-30. [IDIS 176080] [PubMed 6137140]

288. American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: advanced cardiovascular life support. Circulation. 2000;102(Suppl I):I1-384.

289. Reliant Pharmaceuticals, Inc. Rythmol SR (propafenone hydrochloride) extended-release capsules prescribing information. Liberty Corner, NJ; 2005 Dec.

290. Alboni P, Botto GL, Baldi Net al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med. 2004; 351:2384-91. [IDIS 525395] [PubMed 15575054]

291. Gronefeld GC, Hohnloser SH. The “pill-in-the-pocket” approach to atrial fibrillation.N Engl J Med. 2005; 352:1150. Letter. [IDIS 529768] [PubMed 15784671]

292. Konety SH, Olshansky B. The “pill-in-the-pocket” approach to atrial fibrillation.N Engl J Med. 2005; 352:1150. Letter. [IDIS 529769] [PubMed 15789457]

293. Wittkowsky AK. The “pill-in-the-pocket” approach to atrial fibrillation.N Engl J Med. 2005; 352:1150-1. Letter. [IDIS 529770] [PubMed 15789456]

294. Alboni P, Botto GI, Baldi N. The “pill-in-the-pocket” approach to atrial fibrillation.N Engl J Med. 2005; 352:1151. Reply.

295. Botto GL, Capucci A, Bonini W et al. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. Int J Cardiol. 1997; 58:55-61. [PubMed 9021428]

296. Boriani G, Biffi M, Capucci A et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Ann Intern Med. 1997; 126:621-5. [IDIS 383634] [PubMed 9103129]

297. Azpitarte J, Alvarez M, Baun O et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J. 1997; 18:1649-54. [PubMed 9347277]

298. Boriani G, Biffi M, Capucci A et al. Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation. Pacing Clin Electrophysiol. 1998; 21(11 Pt 2):2465-9. [PubMed 9825368]

299. Boriani G, Biffi M, Capucci A et al. Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. Pacing Clin Electrophysiol. 1998; 21(11 Pt 2):2470-4. [PubMed 9825369]

300. Capucci A, Villani GQ, Aschieri D et al. Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study. Int J Cardiol. 1999; 68:187-96. [PubMed 10189007]

301. Alboni P, Tomasi C, Menozzi C et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 2001; 37:548-53. [IDIS 460837] [PubMed 11216977]

302. Capucci A, Lenzi T, Boriani G et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 1992; 70:69-72. [IDIS 298702] [PubMed 1615873]

303. Blanc JJ, Voinov C, Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol. 1999; 84:1029-32. [IDIS 439534] [PubMed 10569658]

304. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol. 2001; 37:542-7. [IDIS 460836] [PubMed 11216976]

305. Boriani G, Martignani C, Biffi M et al. Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment. Drugs. 2002; 62:415-23. [PubMed 11827557]

306. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003; 87:121-8. [PubMed 12559528]

307. Deneer VH, Borgh MB, Kingma JH et al.Oral antiarrhythmic drugs in converting recent onset atrial fibrillation. Pharm World Sci. 2004; 26:66-78. [IDIS 517438] [PubMed 15085940]

308. Reliant Pharmaceuticals, Inc. Product information (RYTH-4002) for Rythmol SR (propafenone hydrochloride) extended-release capsules. Liberty Corner, NJ; 2004 Jan.

309. Reviewers’ comments (personal observations).

310. The American Heart Association. Guidelines 2005 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2005; 112(Suppl I): IV1-211.

Hide
(web1)